News and Announcements
EpiAxis heads to the J.P Morgan 40th Annual Healthcare Conference
- Published November 23, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Following a successful presentation at the Australia-Taiwan Biotech Investment & Partnership Forum earlier this month, EpiAxis Therapeutics will be taking its new corporate presentation to the J.P. Morgan 40th Annual Healthcare Conference.
The conference will be held in San Francisco from January 10-13, 2022.
“The J.P. Morgan 40th Annual Healthcare Conference is the largest and most informative health care investment symposium in the industry,” said EpiAxis CEO Dr Jeremy Chrisp. “It connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.”
In 2021, public and private companies delivered presentations to more than 8000 conference participants.
For 2022, AusBiotech is hosting a virtual Australian Showcase during the conference, highlighting companies at the forefront of medical innovation. EpiAxis will share its new corporate presentation to global investors and potential partners at this conference.
In partnership with AusBiotech, EpiAxis took part in the Australia-Taiwan Biotech Investment & Partnership Forum in early November. Organised by the Australian Office Taipei and the Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO), the forum aimed to connect the biotech and pharma industries in the two nations.
More than 60 guests joined the forum, which was held during the BioTaiwan Exhibition, including several major biotech companies, venture capitalists, BIO industry members, event partners and journalists from bio magazines.
“It was exciting to share the latest updates from EpiAxis with industry and investors in Taiwan,” said Dr Chrisp. “There is great potential for our epigenetics pipeline in the Asian market and we look forward to following up on the valuable connections that were made during the forum.”
About The Company
EpiAxis Therapeutics Pty Ltd (“EpiAxis”) is a privately funded, translational drug development company developing novel epigenetic cancer therapeutics. The Company, which was established in 2015, was based on the pioneering work of Professor Sudha Rao regarding the role of lysine-specific demethylase 1 (“LSD1”) in cancer progression and metastasis. EpiAxis’ key point of differentiation is the way that their LSD1 inhibitors target dormant cancer cells and epigenetically re-programming them back to a normal cell phenotype, thereby decreasing their resistance to therapies, whilst reinvigorating the immune system.
Company Updates
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
